Skip to main content
. 2021 Sep 24;12:749094. doi: 10.3389/fimmu.2021.749094

Figure 3.

Figure 3

Donor cell engraftment is dependent on recipient pre-alloSCT irradiation dose and treatment with BCL2 or JAK1/2 inhibitors. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. The following day mice were treated with RIC and alloSCT. (A) Donor cell engraftment (H2kd+ cells) was measured in the blood at day 21 post-alloSCT. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. Mice (n=3-4/group) were killed on days 1, 2, 3, and 7, and BM was harvested and analysed by flow cytometry for the absolute number of (B–F) NK cells (NK1.1+CD3-), cNK (NKp46+CD49b+), M1 mature (CD11b+CD27+), M2 mature (CD11b+CD27-) and immature (CD11b-CD27+) NK cells; (G–L) naive (N; CD44-CD62L+); central memory (CM; CD44+CD62L+); effector memory (EM; CD44+CD62L-) CD4+ and CD8+ T cells. Data is representative of 3 independent experiments. Statistical analysis was performed using unpaired T test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.